Background {#S0001}
==========

Carbapenems are a category of antibiotics belonging to beta-lactams; they have a broad antimicrobial spectrum and effective antibacterial activity, especially for gram-negative bacilli (GNB). However, the steadily increasing rate of carbapenem-resistant bacteria has become a significant public health problem in recent years,[@CIT0001],[@CIT0002] resulting in increased mortality, lengths of hospital stay and medical expenditures. *Enterobacteriaceae, Acinetobacter* spp. and *Pseudomonas aeruginosa* (*P. aeruginosa*) are the most common gram-negative bacterial species obtained from worldwide clinical samples.

Bloodstream infections (BSIs) are the most severe types of nosocomial infections and lead to poor prognoses, particularly in patients with advanced age, immunosuppression, poor functional status and comorbid conditions. BSIs caused by carbapenem-resistant GNB (CR-GNB) have become a major challenge for clinicians in selecting an effective treatment regimen. Currently, there is still a dearth of therapeutic options even based on in vitro susceptibilities, since the vast majority cases of CR-GNB infection are extensively drug-resistant (XDR) or even pandrug-resistant (PDR). It has been reported that speciﬁc combinations of antibiotics (some of which include carbapenems, sulbactam, tigecycline or colistin) may benefit patients who are infected by CR-GNB.[@CIT0003]--[@CIT0008] Combined therapeutic regimens (two- or three-drug combinations) were recommended in a Chinese consensus statement based on limited clinical studies.[@CIT0009] In addition to one retrospective study conducted in Taiwan,[@CIT0010] no relevant clinical study concerning CR-GNB regimens has been conducted in mainland China. Thus, the issue of antibiotic options for CR-GNB infections remains unresolved.

Herein, we conducted an analysis on the effectiveness of different antibiotic regimens in a retrospective cohort of 175 individuals with BSIs caused by CR-GNB. More clinical evidence will guide the options for therapeutic regimens in the Chinese population.

Methods {#S0002}
=======

Study Design and Patients {#S0002-S2001}
-------------------------

A retrospective observational study was conducted between January 2010 and December 2017 in Huashan Hospital, Fudan University, which is a large academic tertiary hospital in Shanghai, China. The enrolled subjects had at least one blood culture positive for GNB. In vitro susceptibility tests were used to confirm carbapenem resistance. Only the ﬁrst CR-GNB BSI episode was considered, and polymicrobial bacteremia was included in the analysis. Furthermore, the initial targeted antibiotic regimen that was administered for ≥72 hrs was selected.

Patient medical records were reviewed, and the following clinical information was extracted: demographic data, underlying diseases, medical devices, length of hospital stay, length of intensive care unit (ICU) stay, Acute Physiology and Chronic Health Evaluation (APACHE) II score at BSI onset,[@CIT0011] extra-bloodstream infections, antimicrobial agents, and microbiological and clinical outcomes.

Microbiology and Antimicrobial Susceptibility Testing {#S0002-S2002}
-----------------------------------------------------

Species identiﬁcation and susceptibility testing were performed in the hospital's microbiology laboratory using the disk diffusion method according to the Clinical and Laboratory Standards Institute (CLSI) criteria[@CIT0012] or with a Vitek 2 compact automated system (bioMérieux) following the instrument speciﬁcations, and the results were interpreted according to the CLSI criteria.[@CIT0012] For tigecycline, the US Food and Drug Administration interpretive criteria was applied.[@CIT0013] No minimum inhibitory concentration (MIC) data were available.

Deﬁnitions {#S0002-S2003}
----------

The following terms were defined prior to the data analysis. The length of ICU stay was deﬁned as the number of days in the ICU, including the central ICU, neurological care unit, neurosurgical care unit, trauma emergency care unit, liver transplantation care unit, severe infection care unit, etc.

The onset of BSI was deﬁned as the collection date of the blood culture specimen that first yielded the study isolate. Polymicrobial BSI was defined as two or more study organisms present at the same time in a patient's blood according to their culture results. Septic shock was deﬁned as a clinical construct of sepsis within the first 48 hrs of BSI onset with persisting hypotension requiring vasopressors to maintain mean arterial pressure (MAP) ≥65 mmHg and a serum lactate level \>2 mmol/L (or lactate data default) despite adequate volume resuscitation.[@CIT0014]

Immunosuppression was deﬁned as the condition of a patient who received immunosuppressants, chemotherapy, radiation, long-term or recent high-dose steroids, or who had a disease, such as leukemia, lymphoma or acquired immune deficiency syndrome (AIDS), that was sufficiently advanced to suppress resistance to infection.[@CIT0011] Neutropenia was deﬁned in accordance with the Infectious Diseases Society of America (IDSA) guidelines as an absolute neutrophil count (ANC) of \<500 cells/mm^3^ at the onset of BSI.[@CIT0015] Fever was deﬁned as a temperature of ≥38°C that was sustained for more than 1 hr.[@CIT0015] Defervescence was deﬁned as a temperature of ≤37.2°C that was sustained for more than 72 hrs.

The recorded extra-bloodstream infections were diagnosed before the onset of the studied BSI or occurred simultaneously. Intra-abdominal infections (IAIs) were separated into uncomplicated and complicated IAIs. Infection limited to a hollow viscus was considered an uncomplicated IAI, whereas those that extended into a normally sterile area of the abdomen, such as the peritoneal cavity, mesentery, retroperitoneum, another abdominal organ, or the abdominal wall, were deﬁned as complicated IAIs.[@CIT0016] Solid organ abscess included the abscesses in the brain, eye, lung, liver, vertebra, etc. Infectious endocarditis was confirmed by echocardiography.

Carbapenem resistance was deﬁned as drug resistance to any carbapenem according to in vitro susceptibility testing. Only strains confined to *Stenotrophomonas maltophilia* were excluded because of their natural resistance to carbapenems. Antimicrobial treatment for non-gram-negative agents or treatment for less than 72 hrs was considered invalid or inadequate. Antibiotics with known gram-negative activity administered either empirically but consistently or after obtaining the results of the susceptibility testing were deﬁned as "targeted" treatments. Regimens were classiﬁed as monotherapy or combination therapy depending on the number of drugs included.

Treatment success was deﬁned as the eradication of the study organisms according to repeated negative blood cultures; presumed success was defined as clinical cure according to the improvement in symptoms and signs associated with the underlying BSIs if subsequent blood cultures were not performed. Treatment failure was deﬁned by repeated positive blood cultures, clinical deterioration or death attributed to the underlying BSI. The above evaluations were conducted 72 hrs after the initiation of the "targeted" therapy.

Inclusion and Exclusion Criteria {#S0002-S2004}
--------------------------------

Inclusion criteria: individuals with at least one blood culture positive for GNB. Exclusion criteria: individuals without carbapenem resistance; not the first CR-GNB BSI episode; not treated for ≥72 hrs in the initial targeted antibiotic regimen; without antibiotic therapy or treatment of Gram-negative covered antimicrobials; strains confined to *Stenotrophomonas maltophilia*.

Statistical Analysis {#S0002-S2005}
--------------------

The outcomes measured were the all-cause mortality within 28 days after BSI onset, as well as the treatment success or presumed success rates. Patients discharged with an improved condition before day 28 were considered survivors, while those requesting discharge with symptom exacerbation and vital sign instability were considered nonsurvivors. The results are expressed as the mean±standard deviation (SD) or median (interquartile range; IQR) (continuous variables) or as percentages of the group from which they were derived (categorical variables). Student's *t*-test and the Mann--Whitney *U*-test were used to compare normally and non-normally distributed continuous variables, respectively. Categorical variables were evaluated with the χ^2^ or two-tailed Fisher's exact tests. A Cox proportional hazards model was used to identify the factors independently associated with mortality. The sets of variables that were identiﬁed from the univariate analysis as statistically signiﬁcant were entered into the model, and their contribution was assessed using the likelihood ratio test. Two-tailed tests were used to determine statistical signiﬁcance; a P value of \<0.05 was considered signiﬁcant. Data were processed and analyzed using STATA statistical software (StataCorp LP, version 15).

Results {#S0003}
=======

[Figure 1](#F0001){ref-type="fig"} shows the ﬂowchart of the participant selection process. Among the 893 GNB isolates of BSIs from 2010 to 2017, a total of 245 (27.4%) isolates were carbapenem-resistant. Among the 43 individuals who received inadequate treatment, 25 (58.1%) isolates were *Klebsiella pneumoniae* (*K. pneumoniae*), 15 (34.9%) were *Acinetobacter baumannii* (*A. baumannii*), and 2 (4.7%) were *P. aeruginosa*. Rapid death after the onset of BSI occurred in the 36 excluded individuals with less than 72 hrs of treatment. There were 4 patients with both *K. pneumoniae* and *A. baumannii* polymicrobial infection during the first CR-GNB BSI episode. The carbapenem-resistant rate among blood GNB isolates significantly increased from 20.0% in 2013 to 38.6% in 2017 (P = 0.005) ([Figure 2](#F0002){ref-type="fig"}). The characteristics of the 175 individuals (171 patients) who met the inclusion criteria of our study are shown in [Table 1](#T0001){ref-type="table"}. One hundred and twenty-nine individuals (73.7%) were male, and 46 (26.3%) were female. The mean age was 54.6 years (SD, 17.5 years) (median, 57 years; range, 14 to 102 years). Regarding the species of isolates, 85 (48.6%) were *K. pneumoniae*, 8 (4.6%) were *Escherichia coli* (*E. coli*), 54 (30.9%) were *A. baumannii*, and 10 (5.7%) were *P. aeruginosa* ([[Supplementary Table S1](https://www.dovepress.com/get_supplementary_file.php?f=247378.doc)]{.ul}). The probable source of BSI is shown in [[Supplementary Table S1](https://www.dovepress.com/get_supplementary_file.php?f=247378.doc)]{.ul}. In 122 of the individuals, the portal of entry could not be deduced through retrospective observation. Overall, the median length of hospital stay was 32 days (IQR, 22 to 57 days), and the median length of ICU stay was 18 days (IQR, 0 to 40 days). Moreover, the median duration of mechanical ventilation was 4 days (IQR, 0 to 17 days).Table 1Characteristics of Individuals with Bloodstream Infections Caused by CR-GNB According to All-Cause 28-Day MortalityVariablesSurvived (n = 140)Died (n = 35)P valueAge (years), mean (SD)52.7 (17.6)62.1 (15.1)0.004Male, no. (%)105 (75.0)24 (68.6)0.440Comorbidities, no. (%) Solid tumour27 (19.3)7 (20.0)0.924 Haematological malignancy7 (5.0)3 (8.6)0.421 Liver disease  Cirrhosis13 (9.3)1 (2.9)0.307  Hepatitis20 (14.3)3 (8.6)0.576 Post transplantation (solid organ/stem cell)17 (12.1)1 (2.9)0.129 Chronic pulmonary disease6 (4.3)3 (8.6)0.386 Chronic renal failure6 (4.3)0 (0.0)0.601 Acute renal failure4 (2.9)3 (8.6)0.144 Cardiac dysfunction1 (0.7)5 (14.3)0.001 Diabetes20 (14.3)8 (22.9)0.216 Hypertension41 (29.3)15 (42.9)0.124 Vascular disease  Cardiovascular7 (5.0)4 (11.4)0.234  Cerebrovascular24 (17.1)14 (40.0)0.003  Others (macrovascular/peripheral vascular/intestinal vascular)9 (6.4)1 (2.9)0.689 Intracranial infection16 (11.4)3 (8.6)0.769 Non-neoplastic/infectious neurologic diseases9 (6.4)0 (0.0)0.207 Post cardiopulmonary resuscitation5 (3.6)0 (0.0)0.584 Autoimmune diseases2 (1.4)3 (8.6)0.055 Skin disease3 (2.1)0 (0.0)1.000 Gastrointestinal disease  Perforation2 (1.4)5 (14.3)0.004  Others (obstruction/hemorrhage)11 (7.9)2 (5.7)1.000 Trauma28 (20.0)7 (20.0)1.000Clinical findings Immunocompromise, no. (%)56 (40.0)15 (42.9)0.758 Neutropenia, no. (%)6 (4.3)1 (2.9)1.000 Septic shock, no. (%)23 (16.4)15 (42.9)0.001 APACHE II score, median (IQR)18 (13--23)25 (20--34)\<0.001 Surgical procedure besides transplantation, no. (%)59 (42.1)14 (40.0)0.818 Indwelling invasive devices, no. (%)  Central venous catheter/PICC106 (75.7)32 (91.4)0.042  Other catheter (tracheal catheter/nasogastric tube/bladder catheter/surgical drain)113 (80.7)33 (94.3)0.053 Length of hospital stay, median (IQR)34.5 (23.5--69)26 (18--42)0.001 Length of ICU stay, median (IQR)17.5 (0--44)18 (7--26)0.728 Days of mechanical ventilation, median (IQR)1 (0--16.5)13 (6--19)0.001Treatment variables Time to initiation targeted regimen ≤48 h, no. (%)79 (56.4)23 (65.7)0.319 Sustained positivity of blood culture, no. (%)12 (12.2)8 (26.7)0.082 Days to negativity of blood culture, median (IQR)6 (2--10)4 (3--6)0.100 Peak temperature during BSI (°C), mean (SD)39.4 (0.9)39.9 (0.9)0.006 Persistent fever, no. (%)40 (28.8)29 (82.9)\<0.001 Days to defervescence, median (IQR)8 (4--17)7 (2--10)0.369 WBC after targeted regimen (×10^9^/L), median (IQR)  D110.9 (7.1--15.2)11.3 (6.7--18.4)0.490  D39.6 (7.1--13.1)13.3 (7.2--17.6)0.069  D78.8 (6.1--12.4)13.4 (9.9--16.9)0.027 ANC after targeted regimen (×10^9^/L), median (IQR)  D18.7 (5.7--12.5)10.1 (5.9--16.0)0.205  D37.8 (5.3--10.3)11.3 (6.1--17.5)0.007  D77.2 (4.2--9.8)12.0 (7.9--15.3)0.010[^2] Figure 1Flowchart of the study selection process.Figure 2Percentages of resistance to carbapenems among GNB isolates in BSIs throughout the study period.

Treatment {#S0003-S2001}
---------

Antibiotic therapy was selected at the discretion of the attending clinician, and drugs were administered with current standard doses that were adjusted according to creatinine clearance when indicated.[@CIT0017] Most of the isolates lacked in vitro susceptibility data for tigecycline, colistin and fosfomycin. Regarding the targeted treatments, 18 individuals (10.3%) received at least one active drug, while 84 (48.0%) received no active drug within 48 hrs after the onset of bacteremia. Moreover, 37 individuals (21.1%) received at least one active drug, and 36 (20.6%) received therapy with no active drug after the ﬁrst 48 hrs of the BSI. Altogether, 127 individuals (72.6%) received two or more drugs to eliminate the CR-GNB isolate. The remaining 48 individuals (27.4%) received single-drug regimens. The antibiotic regimens are presented in detail in [[Supplementary Table S2](https://www.dovepress.com/get_supplementary_file.php?f=247378.doc)]{.ul}. The individuals in the monotherapy and combination therapy groups were comparable in terms of age, sex, severity of BSI, presence of immunosuppression and neutropenia, severity of sepsis, medical intervention, lengths of hospital and ICU stay, and probable source of BSI ([Table 2](#T0002){ref-type="table"}, [[Supplementary Table S3](https://www.dovepress.com/get_supplementary_file.php?f=247378.doc)]{.ul}). Except for the presence of diabetes, which was higher in the combination therapy group than in the monotherapy group (19.7% versus 6.3%; P = 0.031), all the other comorbidities were comparable between these two groups. Regarding extra-bloodstream infection, both skin and soft tissue infection and solid organ abscess had higher prevalence rates in the combination therapy group than in the monotherapy group.Table 2Characteristics of Individuals with Bloodstream Infections Caused by CR-GNB According to Treatment RegimenVariablesMonotherapy (n = 48)Combination Therapy (n = 127)P valueAge (years), mean (SD)58.6 (17.1)53.1 (17.5)0.064Male, no. (%)35 (72.9)94 (74.0)0.883Comorbidities, no. (%) Solid tumour11 (22.9)23 (18.1)0.473 Haematological malignancy3 (6.3)7 (5.5)1.000 Liver disease  Cirrhosis4 (8.3)10 (7.9)1.000  Hepatitis5 (10.4)18 (14.2)0.512 Post transplantation (solid organ/stem cell)5 (10.4)13 (10.2)1.000 Chronic pulmonary disease4 (8.3)5 (3.9)0.260 Chronic renal failure1 (2.1)5 (3.9)1.000 Acute renal failure4 (8.3)3 (2.4)0.091 Cardiac dysfunction2 (4.2)4 (3.1)0.666 Diabetes3 (6.3)25 (19.7)0.031 Vascular disease  Cerebrovascular14 (29.2)24 (18.9)0.142  Others (cardiovascular/macrovascular/peripheral vascular/intestinal vascular)6 (12.5)15 (11.8)0.900 Intracranial infection5 (10.4)14 (11.0)0.908 Non-neoplastic/infectious neurologic diseases1 (2.1)8 (6.3)0.447 Autoimmune diseases2 (4.2)3 (2.4)0.616 Gastrointestinal disease  Perforation2 (4.2)5 (3.9)1.000  Others (obstruction/hemorrhage)3 (6.3)10 (7.9)1.000  Trauma9 (18.8)26 (20.5)0.799Clinical findings Immunocompromise, no. (%)22 (45.8)49 (38.6)0.383 Neutropenia, no. (%)3 (6.3)4 (3.1)0.394 Septic shock, no. (%)11 (22.9)27 (21.3)0.813 APACHE II score, median (IQR)19 (15.5--24.5)19 (13--24)0.820 Indwelling invasive devices, no. (%)  Central venous catheter/PICC37 (77.1)101 (79.5)0.724  Other catheter (tracheal catheter/nasogastric tube/bladder catheter/surgical drain)38 (79.2)108 (85.0)0.351 Length of hospital stay, median (IQR)34 (20.5--64)32 (22--56)0.786 Length of ICU stay, median (IQR)17.5 (0--41)18 (0--36)0.820 Days of mechanical ventilation, median (IQR)1.5 (0--14.5)6 (0--17)0.365Treatment variables Time to initiation targeted regimen ≤48 h, no. (%)35 (72.9)67 (52.8)0.016 Peak temperature during BSI (°C), mean (SD)39.5 (0.8)39.5 (1.0)0.748 D1 WBC after targeted regimen (×10^9^/L), median (IQR)11.2 (6.0--16.7)10.9 (7.4--15.5)0.704 D1 ANC after targeted regimen (×10^9^/L), median (IQR)8.4 (4.6--14.2)8.9 (6.0--13.3)0.606[^3]

Outcomes {#S0003-S2002}
--------

The all-cause 28-day mortality was 20.0% (35 of 175 individuals died). The effects of host-, infection-, and treatment-related factors on 28-day mortality were assessed with a univariate analysis ([Table 1](#T0001){ref-type="table"}, [[Supplementary Table S1](https://www.dovepress.com/get_supplementary_file.php?f=247378.doc)]{.ul}). Adverse outcomes appeared to be more likely among patients with advanced age, pulmonary infection other than bacteremia, a relatively high APACHE II score, septic shock, an indwelling intravascular catheter, increased time on mechanical ventilation, and comorbidities of cardiac dysfunction, cerebrovascular disease and gastrointestinal perforation than in patients without such conditions. The timing of targeted antimicrobial administration did not have an apparent predictive value for the outcome. Moreover, increased mortality was observed in those with a relatively high peak temperature, persistent fever, and a high level of leukocyte maintenance after therapy was administered for a week. The hospital stay was longer in survivors than in non-survivors because of the 28-day mortality grouping. Surprisingly, mortality seemed to be higher in those treated with combination schemes than in those who received monotherapy (13.4% versus 8.3% for 14-day mortality, 22.0% versus 14.6% for 28-day mortality, and 30.7% versus 25.0% for mortality due to infection), but the difference was not statistically significant ([Table 3](#T0003){ref-type="table"}).Table 3Clinical Outcomes of Individuals with Bloodstream Infections Caused by CR-GNB, According to Type of Antibiotic Regimen, in vitro Susceptibility Tests, and Time to Initiation of Targeted Regimen Containing at Least One Active AgentOutcomesNumber (%) of IndividualsP valueMonotherapy (n = 48)Combination Therapy (n = 127)All-cause 14-day mortality4 (8.3)17 (13.4)0.359All-cause 28-day mortality7 (14.6)28 (22.0)0.271Mortality due to infection12 (25.0)39 (30.7)0.458Treatment success or presumed success rate28 (58.3)75 (59.1)0.931No active agent (n = 120)With active agent (n = 55)All-cause 14-day mortality17 (14.2)4 (7.3)0.193All-cause 28-day mortality24 (20.0)11 (20.0)1.000Mortality due to infection37 (30.8)14 (25.5)0.467Treatment success or presumed success rate67 (55.8)36 (65.5)0.230Initiation of at least 1 active agent ≤48 h\
(n = 18)Initiation of at least 1 active agent \>48 h\
(n = 37)All-cause 14-day mortality2 (11.1)2 (5.4)0.590All-cause 28-day mortality5 (27.8)6 (16.2)0.473Mortality due to infection6 (33.3)8 (21.6)0.510Treatment success or presumed success rate11 (61.1)25 (67.6)0.637

By entering the host-, infection-, and treatment-related variables with potential effects on mortality in the Cox proportional hazards model, the factors of cardiac dysfunction (hazard ratio \[HR\] of death compared to none, 6.02; 95% confidence interval \[CI\], 2.10 to 17.25; P = 0.001), gastrointestinal perforation (HR of death compared to none, 3.28; 95% CI, 1.49 to 7.20; P = 0.003), APACHE II score at the onset of BSI (HR of death per 1-score increase, 1.03; 95% CI, 1.00 to 1.06; P = 0.034), and persistent fever (HR of death compared to none, 1.47; 95% CI, 1.07 to 2.03; P = 0.018) were identiﬁed as independent predictors of adverse outcomes.

The treatment success or presumed success rates were very similar between the monotherapy and combination therapy groups (58.3% versus 59.1%; P = 0.931). Among the different treatment groups, the highest success rate (61.0%) was observed in individuals treated with carbapenem-containing combinations, as shown in [[Supplementary Table S2](https://www.dovepress.com/get_supplementary_file.php?f=247378.doc)]{.ul}. The effect of various treatments was further assessed in different subsets of individuals ([Figure 3](#F0003){ref-type="fig"}). The treatment success rate steadily declined from the highest in all study individuals to the lowest in the most critically ill individuals ([Figure 3A](#F0003){ref-type="fig"}). The protective effects of combination therapy were better than that of monotherapy in those suffering from septic shock, but this advantage was not significant (40.7% versus 18.2%; P = 0.268). There was a therapeutic beneﬁt provided by carbapenems, but the difference was not significant among the different severities of BSIs. Triple or more drug combinations were not superior to double combinations in all the subgroups.Figure 3Treatment success or presumed success rate associated with different antimicrobial drug regimen categories in patients diagnosed as CR-GNB BSIs with different presenting features (**A**), with active agent containing or not (**B**) and with different categories of isolates (**C**).

Further analysis was conducted by classifying treatment regimens as active agent containing or lacking according to the in vitro susceptibility. Increased therapeutic effects could be obtained from the group with at least one active agent, although no significant differences were observed ([Table 3](#T0003){ref-type="table"}). Unexpectedly, when the therapeutic regimen contained an active drug, monotherapy was not inferior to combination therapy ([Figure 3B](#F0003){ref-type="fig"}), despite the slightly lower active agent containing rate in monotherapy than in combination therapy (22.9% versus 34.6%; P = 0.136).

A higher proportion of individuals were administered a targeted monotherapy regimen than combination therapy within 48 hrs (72.9% versus 52.8%; P = 0.016), as shown in [Table 2](#T0002){ref-type="table"}. For the subset of regimens with at least one active agent, the outcome of mortality was not improved, and the success rate was even decreased when treatment began in the ﬁrst 48 hrs of BSI ([Table 3](#T0003){ref-type="table"}).

The infective species were as follows: 101 cases caused by *Enterobacteriaceae* (57.7%), 55 caused by *Acinetobacter* spp. (31.4%), 10 caused by *P. aeruginosa* (5.7%) and 9 caused by other species (5.2%). As shown in [Figure 3C](#F0003){ref-type="fig"}, a slightly increased but nonsignificant success rate was discovered in the monotherapy group for *Enterobacteriaceae* isolates. Carbapenems provided a positive therapeutic effect on BSIs cause by *Enterobacteriaceae* and *P. aeruginosa* isolates. Sulbactam had a certain effect on *Acinetobacter* spp. isolates. In addition to the natural resistance to *P. aeruginosa*, tigecycline had a decreased or vain therapeutic effect on *Enterobacteriaceae* and *Acinetobacter* spp. isolates. All these treatment effects were not statistically significant.

Discussion {#S0004}
==========

Our study conﬁrmed the high mortality and low antimicrobial treatment success rates associated with CR-GNB BSIs, similar to the previous studies.[@CIT0018]--[@CIT0021] The data presented here suggest that cardiac dysfunction, gastrointestinal perforation, the severity of underlying diseases, and response to antibiotic therapy were of paramount importance in determining survival or death. However, the antibiotic regimen did not have a signiﬁcant impact on the outcome of death; compared to monotherapy, combination therapy was not associated with a decreased risk of mortality. This result is quite different from those in previous studies.[@CIT0022]--[@CIT0024]

We selected treatment success or presumed success rates as relatively comprehensive outcomes to evaluate various antimicrobial schemes. The therapeutic effect of combination therapy was not significantly superior to that of monotherapy, even in the septic shock subset, which apparently showed a positive trend for combination therapy. This result may be due to the small sample size in this study, particularly in the subgroups. For *Enterobacteriaceae* isolates, a slightly increased but nonsignificant success rate was associated with monotherapy. More than half of the excluded individuals with less than 72 hrs of treatment were infected with *K. pneumoniae*, resulting in the omission of those who experienced rapid death and were probably infected with hypervirulent *K. pneumoniae*. For the remaining patients with *Enterobacteriaceae* isolates, clinicians had more than 72 hrs to conduct targeted therapy administration. Since some hypervirulent isolates were very likely to be excluded from the study, monotherapy became relatively effective compared to combination therapy. Moreover, this result was also in line with treatment containing at least one active agent; these results are inconsistent with previous studies and can probably be attributed to the influence of the exclusion criteria as well.

To further assess the efﬁcacy of different treatment schemes, we divided the individuals who received combination therapy into different two groups on the basis of treatment with carbapenems, sulbactam or tigecycline. The carbapenem-containing regimens did not produce remarkable therapeutic effects in any of the subgroups, even the *Enterobacteriaceae* or *P. aeruginosa* isolate groups. There was no significant protective effect of sulbactam-containing regimens on BSIs caused by *Acinetobacter* spp. isolates. For tigecycline, no treatment effect was observed in any individuals with BSIs caused by CR-GNB.

Successful treatment was observed when patients were administered treatment with no active agent in our research. This might be attributed to the difficulty of correlating in vitro susceptibility testing with in vivo clinical effectiveness.[@CIT0025] That is, despite in vitro resistance to a certain antibiotic, there may still be activity in vivo. Carbapenems are the most studied antimicrobial drugs that possess this characteristic.

However, the activity of some antibiotics, such as the positive "carbapenem effect", is rather unlikely to occur against CR-GNB, such as carbapenemase-producing *K. pneumoniae* strains (CP-Kps), when their MICs are ≥16 μg/mL. However, in our study, there were 68.6% (120 of 175 individuals) PDR strains, and the MICs of the antibiotics used might have exceeded the upper limits, resulting in nonsignificance between the various antimicrobial regimens.

More individuals were administered the targeted regimen within 48 hrs of BSI onset in the monotherapy group than in the combination therapy group. This might be explained by the fact that only one antibiotic with gram-negative activity was often chosen first for empirical therapy. There was no correlation between the initiation time of therapy and treatment success.

After excluding the patients with rapid death that occurred within 72 hrs of BSI onset, the 48-hr time period to initiate treatment was no longer important. The regimen selection is relatively crucial, especially when choosing proper active agents, regardless of monotherapy or combination therapy.

BSIs caused by CR-GNB is a global challenge. Our research could be considered real-world evidence of the effects of various antimicrobial regimens in the Chinese population, especially in the situation of default MIC values. There were several limitations in this study. As previously mentioned, the sample size, particularly in the monotherapy group, was not large enough because this was a single-center study. Rapid deaths were inevitably eliminated due to inadequate treatment that could not be evaluated. This further led to a reduction in the number of research samples. More real-world, large-scale clinical trials are needed for further research.

Conclusions {#S0005}
===========

The present study reconﬁrms the high mortality and low antimicrobial treatment success rates associated with CR-GNB BSIs. Combination therapy showed a treatment success rate similar to that of monotherapy, but it trended toward effectiveness in patients with severe morbid conditions, such as septic shock. Despite the lack of statistical significance, speciﬁc combinations of antibiotics seemed to be effective for BSIs caused by several speciﬁc kinds of isolates, such as those containing carbapenems for *Enterobacteriaceae* and *P. aeruginosa* isolates, as well as sulbactam for *Acinetobacter* spp. isolates. However, tigecycline did not show any therapeutic effect on BSIs caused by any isolate cultured from the bloodstream. Notably, the appropriate selection of an active agent is more vital to the anti-infection outcome than the treatment regimen alone.

Abbreviations {#S0006}
=============
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